Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1: Long-Term Follow up

被引：0
|
作者：
Marmarelis, M. E. [1 ]
Cantor, D. J. [1 ]
Mathew, D. [1 ]
McWilliams, T. [1 ]
Bauml, J. [2 ]
Hwang, W-T [1 ]
Singh, A. [1 ]
D'Avella, C. [1 ]
Davis, C. [1 ]
Ye, D. [1 ]
Sun, L. [1 ]
Ciunci, C. [1 ]
Aggarwal, C. [1 ]
Cohen, R. B. [1 ]
Minn, A. [1 ]
Wherry, J. [1 ]
Langer, C. J. [1 ]
机构：
[1] Univ Penn, Philadelphia, PA USA
[2] Janssen, Philadelphia, PA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Immunotherapy; JAK; Pembrolizumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA06.04
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [31] Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study
    Glimelius, B.
    Spindler, K. L.
    Frodin, J-E.
    Berglund, A.
    Bystrom, P.
    Qvortrup, C.
    Jakobsen, A.
    Pfeiffer, P.
    ANNALS OF ONCOLOGY, 2010, 21 (05) : 1127 - 1128
  • [32] Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up
    Anna W. Chalmers
    Shiven Patel
    Ken Boucher
    Laura Cannon
    Michelle Esplin
    Julie Luckart
    Natalie Graves
    Terry Van Duren
    Wallace Akerley
    Targeted Oncology, 2019, 14 : 417 - 421
  • [33] ElevatION: NSCLC-101-A Phase 1b Study of PDR001 Combined with Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients
    Vansteenkiste, J.
    Felip, E.
    Shepherd, F.
    Paz-Ares, L.
    Barlesi, F.
    Burgers, S.
    Cai, C.
    Kiertsman, F.
    Scott, J.
    Mcculloch, T.
    Lau, Y. Y.
    Morgensztern, D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2402 - S2402
  • [34] Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
    Chen, Ya
    Wang, Yanan
    Yang, Zhengyu
    Hu, Minjuan
    Zhang, Yanwei
    Qian, Fangfei
    Zhang, Wei
    Zhang, Bo
    Han, Baohui
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [35] Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
    Liu, Qiao
    Zhou, Zhen
    Luo, Xia
    Yi, Lidan
    Peng, Liubao
    Wan, Xiaomin
    Tan, Chongqing
    Zeng, Xiaohui
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [36] A Phase 2/3 Study of Fianlimab plus Cemiplimab versus Cemiplimab in Patients with Advanced NSCLC with Tumors Expressing PD-L1 ≥50%
    Faulkner, Neil
    Nair, Santosh
    Gabrail, Nashat
    Kunta, Gopal
    Ibrahim, Emad
    Dreisbach, Luke
    Brungs, Daniel
    Mani, Jayakumar
    Ghattas, Maria
    Li, Siyu
    Salvati, Mark
    Lowy, Israel
    Hiley, Tara
    Fury, Matthew G.
    Paoluzzi, Luca
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E39 - E39
  • [37] Clinical significance of inter-assay discrepancy in PD-L1 expression evaluation for the efficacy of pembrolizumab in advanced NSCLC patients with high PD-L1 expression
    Miyakoshi, Jun
    Kashima, Jumpei
    Shirasawa, Masayuki
    Torasawa, Masahiro
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Horinouchi, Hidehito
    Shiraishi, Kouya
    Kohno, Takashi
    Yamamoto, Noboru
    Yatabe, Yasushi
    Ohe, Yuichiro
    CANCER RESEARCH, 2024, 84 (06)
  • [38] A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC
    Lisberg, A.
    Cummings, A.
    Goldman, J. W.
    Bornazyan, K.
    Reese, N.
    Wang, T.
    Coluzzi, P.
    Ledezma, B.
    Mendenhall, M.
    Hunt, J.
    Wolf, B.
    Jones, B.
    Madrigal, J.
    Horton, J.
    Spiegel, M.
    Carroll, J.
    Gukasyan, J.
    Williams, T.
    Sauer, L.
    Wells, C.
    Hardy, A.
    Linares, P.
    Lim, C.
    Ma, L.
    Adame, C.
    Garon, Edward B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : 1138 - 1145
  • [39] A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naive Patients with Advanced NSCLC
    Lisberg, A.
    Hunt, J.
    Reese, N.
    Wang, T.
    Coluzzi, P.
    Spiegel, M.
    Bornazyan, K.
    Carroll, J.
    Madrigal, J.
    Ledezma, B.
    Mendenhall, M.
    Bui, J.
    Lu, H.
    Cummings, A.
    Noor, Z.
    Goldman, J. W.
    Garon, E.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1805 - S1805
  • [40] Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
    Piedra, A.
    Recio, S. Martinez
    Gonzalez, A. Hernandez
    Bueno, M. T. Moran
    Arriola, E.
    Recuero-Borau, J.
    Dols, M. Cobo
    Gonzalez, P. Cordeiro
    Martinez, J. Mosquera
    Garcia-Campelo, M. R.
    Blanco, A. Calles
    Alvarez, R. M.
    Garcia, M. Zapata
    Casado, M. D. Isla
    Perez, A. Callejo
    Gomez, P. Iranzo
    Joaquin, A. Barba
    Sullivan, I. G.
    Felip, E.
    Majem, M.
    ANNALS OF ONCOLOGY, 2023, 34
12345